Clinical Trial Update: Dose-escalation, Repeated and Single Oral Dosing Study [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of an IlDong Pharmaceutical compound in acute coronary syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• undisclosed

Snippet

Sponsor: IlDong Pharmaceutical Co Ltd | Conditions: Acute Coronary Syndrome | Phase 1 | Status: TERMINATED